No matches
Pulmonology

Corticosteroids in Asthma Management

This infographic illustrates the ongoing burden associated with maintenance oral corticosteroid (OCS) use and high-dose inhaled corticosteroids (ICS) in asthma, including the clinical impact of corticosteroid exposure, supporting evidence, and the importance of considering corticosteroid burden in asthma management.

Related resources

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

expert video
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

expert video
ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

expert video
ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
Screen depicting a mucus plug in the airways

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

videoanimation
Understanding IL-33: A Key Factor in COPD Pathogenesis

Understanding IL-33: A Key Factor in COPD Pathogenesis

interactivity
ERS 2024 | What Do We Know About IL-33 Genetics?

ERS 2024 | What Do We Know About IL-33 Genetics?

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

Podcast
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

expert video
ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

expert video
ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

Podcast
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

Podcast
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

videoanimation
Mechanisms of Production and Clinical Impact of IgE

Mechanisms of Production and Clinical Impact of IgE

videoanimation
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

Infographic
How Type 2 Inflammation Drives Eosinophils in Asthma

How Type 2 Inflammation Drives Eosinophils in Asthma

videoanimation
Exploring the Mechanisms of FeNO Production in the Lungs

Exploring the Mechanisms of FeNO Production in the Lungs

videoanimation
Eosinophils: A Biomarker in COPD

Eosinophils: A Biomarker in COPD

Infographic
ERS 2025 | The Knowns and Unknowns in the COPD Landscape

ERS 2025 | The Knowns and Unknowns in the COPD Landscape

expert video
ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

expert video
Understanding the Clinical Impact of Mucus Plugs in COPD

Understanding the Clinical Impact of Mucus Plugs in COPD

Infographic
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

videoanimation
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Infographic
How Can FeNO Measurement Improve Severe Asthma Management?

How Can FeNO Measurement Improve Severe Asthma Management?

expert video
Worsening Disease Results in a Vicious Cycle of COPD

Worsening Disease Results in a Vicious Cycle of COPD

interactivity
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

interactivity
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity
On-Treatment Asthma Remission Infographic

On-Treatment Asthma Remission Infographic

Infographic
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
Lung Function Decline: Why it Matters and What’s at Stake for Patients

Lung Function Decline: Why it Matters and What’s at Stake for Patients

interactivity
Pathways Driving Chronic Airway Remodeling in Asthma

Pathways Driving Chronic Airway Remodeling in Asthma

videoanimation
On-Treatment Asthma Remission Infographic

On-Treatment Asthma Remission Infographic

interactivity
The Compounded Burden of CRSwNP and Asthma

The Compounded Burden of CRSwNP and Asthma

interactivity

Learning objectives

  • Recognize the burden associated with OCS in asthma management
  • Understand the risks associated with higher-dose ICS exposure in asthma management
Tags
asthma
MAT-US-2609743 v1.0 - P 09/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region